Zhengye Biotechnology Holding Business Summary

Zhengye Biotechnology Holding Ltd (ZYBT) operates as a vertically integrated manufacturer specializing in the research, development, and commercialization of veterinary vaccines, primarily targeting the Chinese livestock market. The company generates revenue through the direct sale of monovalent, polyvalent, and combined vaccines to large-scale livestock producers and local government agencies, as well as through a network of domestic and international distributors. Its primary business segments are categorized by animal species, with swine vaccines historically serving as the largest revenue driver, followed by poultry and cattle/sheep vaccines. ZYBT is currently executing a strategic pivot to diversify its portfolio into the companion animal sector and expand its export footprint in Vietnam, Pakistan, and Egypt. In the competitive landscape, ZYBT contends with major domestic peers such as Jinyu Bio-technology, Pulike Biological Engineering, and China Animal Husbandry Industry Co., Ltd. (CAHIC). While smaller in market capitalization than these leaders, ZYBT differentiates itself through a high-density R&D pipeline and a specialized focus on high-growth segments like the PCV2 and PCV3 swine vaccines. The company’s leadership is anchored by Chairman Zhenfa Han, who has overseen the core operating entity, Jilin Zhengye Biological Products, for over two decades. The executive team is currently structured under a dual-leadership model featuring Co-CEOs Songlin Song and Aiden Han. Songlin Song brings deep operational expertise, having served as General Manager of the Jilin subsidiary since its formative years, while Aiden Han, appointed Co-CEO in March 2025, provides a modern strategic perspective with a business background from the University of Southern California. The company successfully transitioned to the public markets with a Nasdaq listing in January 2025, attracting institutional backing from notable firms including Jane Street Group, Invesco Ltd., and Geode Capital Management. The board of directors remains relatively lean and recently refreshed, focusing on governance and the company’s 2026 strategic priorities of digital transformation and laboratory-based customer service ecosystems.